Cargando…
A case report: rapid progression of coronary atherosclerosis in a patient taking Targretin (Bexarotene)
Anti-neoplastic drugs have made major advancements in oncology, however they are not without cardiovascular consequences. We present a patient with cutaneous T-cell lymphoma receiving Targretin therapy who presented with accelerated atherosclerosis. His triglyceride level (TG) was greater than 1000 ...
Autores principales: | DeAngelo, Sean, Mann, Kailyn I., Abdulbasit, Muhammad, Ahnert, Amy, Sundlöf, Deborah W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734706/ https://www.ncbi.nlm.nih.gov/pubmed/33308287 http://dx.doi.org/10.1186/s40959-020-00087-3 |
Ejemplares similares
-
A selective retinoid X receptor agonist bexarotene (LGD1069, targretin) inhibits angiogenesis and metastasis in solid tumours
por: Yen, W-C, et al.
Publicado: (2006) -
Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses
por: ROUANET, Jacques, et al.
Publicado: (2022) -
A Novel Co-Crystal of Bexarotene and Ligustrazine Improves Pharmacokinetics and Tissue Distribution of Bexarotene in SD Rats
por: Ren, Shuyue, et al.
Publicado: (2020) -
Prior Bexarotene or Phototherapy Does Not Affect Response to Chlormethine Gel: Post Hoc Analysis of a Pivotal Trial
por: ASSAF, Chalid, et al.
Publicado: (2023) -
Photodegradation of Bexarotene and Its Implication for Cytotoxicity
por: Kryczyk-Poprawa, Agata, et al.
Publicado: (2021)